Krishnan S Hajela

Dr. Krishnan S Hajela

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2010 in Immunology
Verified
Journal Article
Open access
PDF file
KGKrishana C. Gulla
Krishana C. Gulla
KGKshitij Gupta
Kshitij Gupta
AKAnders Krarup
Anders Krarup
PGPeter Gal
Peter Gal
WSWilhelm J. Schwaeble
Wilhelm J. Schwaeble
KHKrishnan S Hajela
Krishnan S Hajela
Summary: The lectin pathway of complement is activated upon binding of mannan‐binding lectin (MBL) or ficolins (FCNs) to their targets. Upon recognition of targets, the MBL‐and FCN‐associated serine proteases (MASPs) are activated, allowing them to generate the C3 convertase C4b2a. Recent findings indicate that the MASPs also activate components of the coagulation system. We have previously shown that MASP‐1 has thrombin‐like activity whereby it cleaves and activates fibrinogen and factor XIII. MASP‐2 has factor Xa‐like activity and activates prothrombin through cleavage to form thrombin. We now report that purified L‐FCN‐MASPs complexes, bound from serum to N‐acetylcysteine‐Sepharose, or MBL‐MASPs complexes, bound to mannan‐agarose, generate clots when incubated with calcified plasma or purified fibrinogen and factor XIII. Plasmin digestion of the clot and analysis using anti‐D‐dimer antibodies revealed that the clot was made up of fibrin and was similar to that generated by thrombin in normal human plasma. Fibrinopeptides A and B (FPA and FPB, respectively) were released after fibrinogen cleavage by L‐FCN‐MASPs complexes captured on N‐acetylcysteine‐Sepharose. Studies of inhibition of fibrinopeptide release indicated that the dominant pathway for clotting catalysed by the MASPs is via MASP‐2 and prothrombin activation, as hirudin, a thrombin inhibitor that does not inhibit MASP‐1 and MASP‐2, substantially inhibits fibrinopeptide release. In the light of their potent chemoattractant effects on neutrophil and fibroblast recruitment, the MASP‐mediated release of FPA and FPB may play a role in early immune activation. Additionally, MASP‐catalysed deposition and polymerization of fibrin on the surface of micro‐organisms may be protective by limiting the dissemination of infection.

18 April 2023 in Inflammation
Verified
Journal Article
Closed access
PDF file
USUzma Saqib
Uzma Saqib
SMSreepadaarchana Munjuluri
Sreepadaarchana Munjuluri
SSSutripta Sarkar
Sutripta Sarkar
SBSubir Biswas
Subir Biswas
OMOyshi Mukherjee
Oyshi Mukherjee
KHKrishnan S Hajela
Krishnan S Hajela

12 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
USUzma Saqib
Uzma Saqib
MPMonika Pandey
Monika Pandey
AVAnjali Vyas
Anjali Vyas
PPPreeti Patidar
Preeti Patidar
SHSumati Hajela
Sumati Hajela
Alexander G. ObukhovAlexander G. Obukhov
Alexander G. Obukhov
Lipoxins were discovered 40 years ago, and since then, their beneficial roles for human health have been confirmed in numerous studies. These small molecules belong to the eicosanoid class of compounds, which are generated metabolically by lipoxygenases. Lipoxins are released during various diseases and conditions, including but not limited to systemic inflammation, infection, asthma, cancer, diabetes, and cardiovascular disorders. Recently, several synthetic lipoxin analogs have been developed that also exhibit potent anti-inflammatory properties. In this review, we discuss the inflammation-resolving roles of lipoxins in various major diseases. Further, we summarize the latest reports on the use of synthetic lipoxins as potential therapeutic agents and discuss the role of aspirin-dependent lipoxin production in alleviating various diseases, including cancer.


20 June 2022 in Indian Journal of Clinical Biochemistry
Verified
Journal Article
Closed access
PDF file
BKBandana Kumari
Bandana Kumari
KHKrishnan S Hajela
Krishnan S Hajela
Asgar AliAsgar Ali
Asgar Ali
ASABHAY KUMAR SHARMA
ABHAY KUMAR SHARMA
RYRajesh Kumar Yadav
Rajesh Kumar Yadav
SSSADHANA SHARMA
SADHANA SHARMA

1 May 2008
Verified
Journal Article
Closed access
KGKshitij Gupta
Kshitij Gupta
RGR K Gupta
R K Gupta
KHKrishnan S Hajela
Krishnan S Hajela